Early phase challenges for biotechs

Have you optimised the early phases of your clinical trials? Doing so is critical both for establishing a thorough understanding of the investigational product’s behaviour in humans and facilitating decision-making throughout the clinical trial process. Approaching early phase trials strategically and anticipating obstacles can be critical to the later success of a therapeutic. For biotechs, which often have fewer resources and face pressure to proceed through trials quickly, there is little room for error. This whitepaper delves into key considerations for early phase trials for biotechs, as well as how emerging modalities and multi-indication targets are impacted by them. Fill in your details to find out more.